A look at the data presented at ESMO for ovarian cancer treatments including the Phase 2 PICCOLO trial of Elahere in PSOC.

Executed on:Oct 22, 2024 9:30 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of Toronto

Professor and Chair of the division of Gynecologic Oncology at the University of Toronto, and Sunnybrook Health Sciences Center. 
Currently manages 200 patients with ovarian cancer.
Interests and expertise include clinical trials, germ cell tumours, Gestational Trophoblastic Disease, Cervical Cancer (innovative surgical approaches, sentinel lymph nodes, and fertility sparing approaches), and Radical and Reconstructive Surgical Techniques in Gynecologic Oncology. 
Author of over 200 peer reviewed publications; Member of MAGIC a multidisciplinary multicooperative group team developing protocols in Malignant Germ Cell Tumours, and previous co-chair of the cervical cancer task force for the NCI (US). 

Interview Goal

On this call we will also be discussing follower FRa ADCs (such as Rina-S and AZD5335),ADC alternative targets (like CLDN6, CDH6) and their potential role in treatment, as well as the potential role of Brenetafusp in ovarian cancer.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.